Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Juni 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in...
13. Juni 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics to Present at the BIO International Convention

NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
05. Juni 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting

Bone marrow response to rigosertib was evaluated as a surrogate for survival in this trial of 64 patients who had previously failed Hypomethylating Agent therapy22% of patients achieved marrow...
22. Mai 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

Clinical and Non-clinical Data Evaluating Oral Rigosertib Plus Azacitidine Combination Therapy SymBio, Onconova’s Partner in Japan, to Present Phase 1 Data Evaluating Oral Rigosertib as a Single...
18. Mai 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting

NEWTOWN, Pa., May 18, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
15. Mai 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results

NEWTOWN, Pa., May 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
04. Mai 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results

NEWTOWN, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
01. Mai 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes

NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
26. April 2017 17:25 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics Announces Closing of Public Offering of Common Stock

NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug...
26. April 2017 08:30 ET | Quelle: Onconova Therapeutics

Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC

NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to...

Vorherige Seite